Substance Use Disorder

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

According to this pioneer, mental health professionals should embrace a new mindset: to consider how to can apply expertise not only within the confines of the exam room, but in boardrooms, in startups, in classrooms, and in community centers.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

Female offenders in the criminal justice system are more likely to have experienced trauma and are more likely to be diagnosed with conditions such as PTSD and depression compared with male offenders.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

March 17 through March 23 is National Drug and Alcohol Facts Week 2025.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

Why are older patients turning to cannabis for symptom relief?

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.

How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?

Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.

While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!

Inhalant use disorder is a form of substance use disorder characterized by the intentional inhalation of volatile substances for their psychoactive effects.

As a treatment, low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects.

Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.

This book seeks to reduce the stigma surrounding teen pregnancy.